Risk-adapted survival benefit of IMRT in early-stage NKTCL: a multicenter study from the China Lymphoma Collaborative Group.
Wu T, Yang Y, Zhu SY, Shi M, Su H, Wang Y, He X, Xu LM, Yuan ZY, Zhang LL, Wu G, Qu BL, Qian LT, Hou XR, Zhang FQ, Zhang YJ, Zhu Y, Cao JZ, Lan SM, Wu JX, Hu C, Qi SN, Chen B, Li YX.
Wu T, et al. Among authors: xu lm.
Blood Adv. 2018 Sep 25;2(18):2369-2377. doi: 10.1182/bloodadvances.2018021311.
Blood Adv. 2018.
PMID: 30242098
Free PMC article.